Navigation Links
AspenBio Pharma Closes $18.2 Million Private Placement of Common Stock
Date:12/24/2007

CASTLE ROCK, Colo., Dec. 24 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has closed a previously announced equity financing with a group of existing and new investors. $18.2 million in gross proceeds were generated from the sale of approximately 2.5 million shares of the company's common stock.

Net proceeds to AspenBio totaled approximately $17.1 million and will be used to fund research and development, product development, FDA approval related activities, working capital, and general corporate purposes. Oppenheimer & Co. Inc., acted as placement agent for the transaction.

Richard Donnelly, CEO and president, commented, "We are fortunate to finalize this offering during a very challenging period in the financial markets. This funding will support AspenBio's continued product development and near term FDA approval goals, like approval of our breakthrough blood screen test for appendicitis. As we recently announced, as a result of our official pre-IDE response from FDA, we are now following the preferred FDA 510k clearance pathway. The funds will also support a number of other exciting initiatives in 2008 designed to enhance shareholder value."

The shares of AspenBio's common stock issued in connection with the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"). Accordingly, these securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.

AspenBio has agreed to file within 30 d
'/>"/>

SOURCE AspenBio Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AspenBio Pharma Reports Second Quarter 2007 Results
2. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
3. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
4. AspenBio Pharma to Present the Edgewater Research Investor Conference
5. AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference
6. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
7. AspenBio Pharma Announces $18 Million Private Placement of Common Stock
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014   GenoSpace , a precision ... of tools to enable the broad use of genomic ... it has been awarded Phase I of a Fast ... National Institutes of Health (NIH) to enable enhanced data ... - http://photos.prnewswire.com/prnh/20140922/147649 During the ...
(Date:9/23/2014)... September 23, 2014 Dr. Williams says, ... book on healthcare offers a three phase process that ... healthcare delivery system that would go far beyond anything ... regarding the delivery of healthcare.” , “Every effort to ... failed to provide discernable progress throughout that system because ...
(Date:9/22/2014)... treated with a statin in the hospital after suffering ... survive than those who were not, according to a ... study was conducted by the same researchers who recently ... survival in victims of ischemic stroke., Ischemic stroke is ... vessel that blocks blood from reaching areas of the ...
(Date:9/22/2014)... by researchers at the USC Viterbi School of ... 3-D microfluidic system quickly and cheaply by simply ... Microfluidic systems are used in many fields including ... volumes of fluids for use in applications such ... diagnostic testing, and synthetic chemistry. Traditionally, microfluidic devices ...
Breaking Biology Technology:GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5
... a material in which an electric field can control the ... effect discovered by the Rutgers group can be extended to ... bits in ultra high-density data storage. The research appears in ... The researchers found the effect by studying the magnetic properties ...
... ROCKVILLE, Md., Aug. 22 A research team co-led by ... Institute for Genome Sciences (IGS), University of Maryland School of ... bean ( Ricinus communis ) genome in Nature Biotechnology ... IGS were co-lead authors on the paper describing the 4.5X ...
... Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using... -- BRUSSELS, August 19, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 2Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 3Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 2Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 3Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 4Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 5Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 6Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 7
(Date:9/23/2014)... has secured $21 million in a Series C Financing. ... Company,s cancer immunotherapy pipeline and advance its lead programs ... round, with participation from Majuven and all existing major ... Venture Capital. , Eureka is engaged in the ... the functions of a T cell receptor, a key ...
(Date:9/23/2014)... majority of drugs used to treat asthma today are the ... are urgently needed to treat this chronic respiratory disease, which ... to wheeze, cough, and find it difficult at best to ... is tough: asthma is a patient-specific disease, so what works ... animal models traditionally used to test new drug candidates often ...
(Date:9/23/2014)... infant chimpanzees from their mothers are well documented, little ... of early life experience. In a year-long study, scientists ... that those who were removed from their mothers early ... performers are likely to show behavioral and social deficiencies ... in the open-access journal PeerJ , was led ...
Breaking Biology News(10 mins):Airway muscle-on-a-chip mimics asthma 2Airway muscle-on-a-chip mimics asthma 3Chimpanzees raised as pets or performers suffer long-term effects on their behavior 2
... days after Hurricane Sandy hit, NJIT Professor Michel Boufadel was ... impact of the storm on the New Jersey shoreline. ... take a team of eight researchers to the beaches of ... five students is still fanning out over the shoreline ...
... in Spanish . U.S. Department of ... against sand flies, which are major pests in Afghanistan, Africa ... vectors of Leishmania parasites that cause leishmaniasis, a devastating disease ... who are bitten by infected sand flies do not know ...
... way foot and mouth disease will be controlled in ... emerging poultry viruses, Two new research projects have ... most devastating livestock and poultry viruses. The two projects, ... (BBSRC), aim to provide novel solutions to combatting the ...
Cached Biology News:NJIT civil engineer receives NSF grant to study storm's impact on Jersey Shore 2Protecting US troops against sand flies 2£12 million funding to tackle devastating livestock and poultry viruses 2£12 million funding to tackle devastating livestock and poultry viruses 3£12 million funding to tackle devastating livestock and poultry viruses 4
Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
Request Info...
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
Biology Products: